Drug news

FDA accepts NDA for IDP 118, a topical treatment for plaque psoriasis.- Ortho Dermatologics/Valeant.

Read time: 1 mins

Last updated:3rd Nov 2017

Published:3rd Nov 2017

Source: Pharmawand

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced that the FDA has accepted the New Drug Application (NDA) for IDP 118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018. If approved, IDP 118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.The most common adverse events were contact dermatitis (7.4%) and application site pain. (2.6%).

Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Learning Zone Homepage

Improving treatment options for childhood psoriasis

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news